A mitochondria-targeted peptide restored fertility in aged mice — in mice

Female fertility fails long before the rest of the body does, and the egg cell is the weak link. Eggs carry more mitochondria than any other cell, and with age those mitochondria drift out of position, leak reactive oxygen and stop supporting the machinery that separates chromosomes. A new study in Aging Cell, from a team at Nanjing Agricultural University, tested whether a drug built for mitochondria could reverse that — and in aged mice, the answer was a qualified yes.

What did the researchers test?

The drug is elamipretide (SS-31), a four-amino-acid peptide that binds cardiolipin, a signature lipid of the inner mitochondrial membrane. It already has an FDA approval — for Barth syndrome, a rare genetic disorder of cardiolipin — which makes it an attractive repurposing candidate. The team injected it into the abdomens of female mice aged 8, 10 and 12 months, when mouse fertility has largely collapsed, trying doses of 3, 5 and 10 mg/kg per day for 3, 7 or 10 days.

One regimen stood out: 5 mg/kg for seven days. Ten-month-old mice on that schedule released roughly two and a half times as many eggs after hormone stimulation as untreated old mice — about 23 versus about 9. More of those eggs fertilized, far more embryos reached the four-cell stage, and under the microscope the treated eggs had tidier spindles, better-aligned chromosomes, lower reactive oxygen and mitochondria back in position around the spindle.

What improved — and by how much?

The numbers deserve their full context. Treated old mice delivered about 2.5 pups per litter against about 0.5 untreated — a real change from near-zero, but under a fifth of the roughly 14 pups young mice deliver, and the benefit was gone within a month. In 12-month-old mice it barely registered. The dose response wasn't linear either: 10 mg/kg did worse than 5, and longer courses didn't help.

The mechanism is the least settled part. Metabolite profiling pointed to vitamin B6 metabolism — and adding B6 to a culture dish did improve old-egg maturation — while gene-expression analysis pointed at VEGF signaling. But the paper's own figures show VEGF-pathway proteins elevated in old eggs and lowered by elamipretide, which reads more like inhibition than the "activation" the abstract claims. The authors themselves describe the B6–VEGF link as speculation.

Why the human-egg results need caution

The team also matured immature eggs discarded from human IVF cycles in a dish with or without elamipretide. In women 35 and over, 79 percent of treated eggs matured within 48 hours against 60 percent of controls, with higher fertilization and cleavage rates — but the paper reports no statistical test, and recomputation from the published counts suggests none of the differences clears conventional thresholds. In women under 35, treated eggs actually fertilized less often. No blastocysts, chromosome counts, pregnancies or births were measured in human material.

The fair summary: this is a reasonable case that egg mitochondria remain a druggable target late in reproductive life in mice, using a compound that already has a regulatory approval. It is not evidence that the drug improves a woman's chance of a baby. Anyone pursuing fertility treatment should treat this as an early laboratory lead — nothing more.

Where the evidence stands

• Established: Egg mitochondria decline with reproductive age; elamipretide is FDA-approved for Barth syndrome and binds mitochondrial cardiolipin.
• Preliminary: Fertility gains shown in aged mice at one dose and schedule; effects faded within a month and were weak at the oldest ages.
• Absent: No demonstrated human fertility benefit — the human-egg dish experiments lack statistical significance and measured no pregnancies or births.